PRRSV Vaccine G16X: Immune Response in Pigs
- A new, non-pathogenic active vaccine, utilizing strain G16X, has shown promising results in controlling Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) in both sows and piglets within a...
- The research demonstrated that vaccination of sows elicited a notable immune response, effectively transferring protective immunity to their piglets.
- PRRSV remains a significant economic burden for the swine industry worldwide. This vaccine offers a potential tool for producers seeking to enhance biosecurity and reduce the impact of...
Novel PRRSV Vaccine Demonstrates Robust Immune Response in Commercial Setting
Table of Contents
Published December 8, 2024
PRRSV Vaccine Efficacy Confirmed in Full-Cycle Farm
A new, non-pathogenic active vaccine, utilizing strain G16X, has shown promising results in controlling Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) in both sows and piglets within a commercial swine production system. The study focused on evaluating the immune response generated by the vaccine across a complete production cycle.
Sow and Piglet Immune Response
The research demonstrated that vaccination of sows elicited a notable immune response, effectively transferring protective immunity to their piglets. This passive immunity, combined with the piglets’ own active immune response following vaccination, contributed to a reduction in PRRSV-related clinical signs and improved overall health. The vaccine’s non-pathogenic nature is a key advantage, minimizing the risk of unintended consequences associated with modified-live vaccines.
Implications for PRRSV Control
PRRSV remains a significant economic burden for the swine industry worldwide. This vaccine offers a potential tool for producers seeking to enhance biosecurity and reduce the impact of PRRSV outbreaks. The prosperous presentation of efficacy in a full-cycle commercial farm setting strengthens the case for its wider adoption.